Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
This study is ongoing, but not recruiting participants.
Study NCT00304278   Information provided by Southern Illinois University

First Received on March 16, 2006.   Last Updated on July 22, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
Erlotinib (Tarceva)
Intra-arterial Cisplatin (PLAT)
Radiation Therapy (RAD)
Additional drug interventions recognized in this trial
Cisplatin
Erlotinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Southern Illinois University
Genentech
OSI Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services